Autoantibodies to Abl and Bcr proteins

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The Bcr-Abl fusion protein, resulting from the Philadelphia chromosome, is a key driver in chronic myeloid leukemia (CML).
• Normal Abl and Bcr proteins play vital roles in cellular functions.
• The immune system's response to these proteins in leukemia is not fully understood.

Purpose of the Study:

• To investigate the presence and nature of autoantibodies against the Bcr-Abl protein and its normal counterparts (Abl and Bcr).
• To determine if autoantibodies are specific to Philadelphia chromosome-positive leukemias or also present in other conditions and healthy individuals.

Main Methods:

• Immunoprecipitation and immunoblotting techniques were employed to detect autoantibodies in patient plasma.
• Baculovirus-expressed Abl and Bcr proteins were used to assess antibody recognition.

Main Results:

• Autoantibodies recognizing the p210Bcr-Abl protein were found in 58% of individuals tested, including 70% of Ph-positive CML patients.
• Antibodies against normal Abl protein were detected in all individuals with autoantibodies against p210Bcr-Abl.
• Antibodies against normal Bcr protein were identified in a subset of these patients.

Conclusions:

• A humoral immune response, characterized by autoantibodies, to p210Bcr-Abl is present in both Philadelphia chromosome-positive and -negative leukemias, as well as in healthy individuals.
• These autoantibodies primarily target the normal Abl protein and, to a lesser extent, the normal Bcr protein.
• The findings suggest a broader autoimmune phenomenon potentially linked to Abl and Bcr proteins in various hematologic states.